Boston Scientific: Two Is Better Than One In European DES Market
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific expects the presence of a second competitor in Europe to significantly speed up the presently sluggish conversion of the bare metal stent market to their drug-eluting counterparts